These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32862776)

  • 1. Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy.
    Zhu L; Ding Z; Li X; Wei H; Chen Y
    Mol Imaging; 2020; 19():1536012120934957. PubMed ID: 32862776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of NGR-based anti-cancer agents for targeted therapeutics and imaging.
    Wang RE; Niu Y; Wu H; Hu Y; Cai J
    Anticancer Agents Med Chem; 2012 Jan; 12(1):76-86. PubMed ID: 22023047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neovasculature homing motif NGR: more than meets the eye.
    Corti A; Curnis F; Arap W; Pasqualini R
    Blood; 2008 Oct; 112(7):2628-35. PubMed ID: 18574027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.
    Di Matteo P; Curnis F; Longhi R; Colombo G; Sacchi A; Crippa L; Protti MP; Ponzoni M; Toma S; Corti A
    Mol Immunol; 2006 Apr; 43(10):1509-18. PubMed ID: 16337683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
    Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
    Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature.
    Zou M; Zhang L; Xie Y; Xu W
    Anticancer Agents Med Chem; 2012 Mar; 12(3):239-46. PubMed ID: 22263803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of
    Satpati D; Sharma R; Sarma HD; Dash A
    Chem Biol Drug Des; 2018 Mar; 91(3):781-788. PubMed ID: 29130625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors.
    Curnis F; Fiocchi M; Sacchi A; Gori A; Gasparri A; Corti A
    Nano Res; 2016 May; 9(5):1393-1408. PubMed ID: 27226823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature.
    Ma W; Li G; Wang J; Yang W; Zhang Y; Conti PS; Chen K
    Amino Acids; 2014 Dec; 46(12):2721-32. PubMed ID: 25182731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NGR peptide ligands for targeting CD13/APN identified through peptide array screening resemble fibronectin sequences.
    Soudy R; Ahmed S; Kaur K
    ACS Comb Sci; 2012 Nov; 14(11):590-9. PubMed ID: 23030271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
    Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
    Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of
    Zhao M; Yang W; Zhang M; Li G; Wang S; Wang Z; Ma X; Kang F; Wang J
    Tumour Biol; 2016 Sep; 37(9):12123-12131. PubMed ID: 27220318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor vasculature targeting through NGR peptide-based drug delivery systems.
    Corti A; Curnis F
    Curr Pharm Biotechnol; 2011 Aug; 12(8):1128-34. PubMed ID: 21470145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
    Dunne M; Zheng J; Rosenblat J; Jaffray DA; Allen C
    J Control Release; 2011 Sep; 154(3):298-305. PubMed ID: 21640146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature.
    Mukhopadhyay S; Barnés CM; Haskel A; Short SM; Barnes KR; Lippard SJ
    Bioconjug Chem; 2008 Jan; 19(1):39-49. PubMed ID: 17845003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminopeptidase N (CD13) targeted MR and NIRF dual-modal imaging of ovarian tumor xenograft.
    Meng Y; Zhang Z; Liu K; Ye L; Liang Y; Gu W
    Mater Sci Eng C Mater Biol Appl; 2018 Dec; 93():968-974. PubMed ID: 30274135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.
    Corti A; Curnis F; Rossoni G; Marcucci F; Gregorc V
    BioDrugs; 2013 Dec; 27(6):591-603. PubMed ID: 23743670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A unified mechanism for aminopeptidase N-based tumor cell motility and tumor-homing therapy.
    Liu C; Yang Y; Chen L; Lin YL; Li F
    J Biol Chem; 2014 Dec; 289(50):34520-9. PubMed ID: 25359769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of NGR peptide-based agents for tumor imaging.
    Wang RE; Niu Y; Wu H; Amin MN; Cai J
    Am J Nucl Med Mol Imaging; 2011; 1(1):36-46. PubMed ID: 23133793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells.
    Wang X; Wang Y; Chen X; Wang J; Zhang X; Zhang Q
    J Control Release; 2009 Oct; 139(1):56-62. PubMed ID: 19470394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.